Artiva Biotherapeutics (ARTV) Total Liabilities (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Total Liabilities data on file, last reported at $18.1 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 19.45% year-over-year to $18.1 million in Q1 2026; TTM through Mar 2026 was $18.1 million, a 19.45% decrease from a year earlier, with the FY2025 full-year figure at $21.0 million, down 8.59% from the prior year.
• Total Liabilities for Q1 2026 stood at $18.1 million, down from $21.0 million in the prior quarter.
• Over the last five years, Total Liabilities for ARTV reached as high as $50.7 million in Q4 2023 and fell as low as $18.1 million in Q1 2026.
• Historically, Total Liabilities has averaged $27.8 million across 4 years, with a median of $22.5 million in 2025.
• On a YoY basis, Total Liabilities climbed as much as 8.59% in 2025 and fell as far as 59.78% in 2025.
• Year by year, Total Liabilities stood at $50.7 million in 2023, then tumbled by 54.77% to $22.9 million in 2024, then slipped by 8.59% to $21.0 million in 2025, then dropped by 13.65% to $18.1 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $18.1 million in Q1 2026, $21.0 million in Q4 2025, and $19.6 million in Q3 2025.